Logo
Pharmidex are delighted to be one of sixteen partners in an EU Horizon 2020 grant - HeatNMof
April 12, 2022

HeatNMof is a heating-triggered drug release from nanometric metal-organic framework composites

The Initial Training Network HeatNMof aims to develop high quality training opportunities for 12 early-stage-researchers (ESRs) in the area of materials science, advanced characterization and biomedicine.


HeatNMof is training the next generation of materials scientists in nanomedicine to exploit heat-triggered release for delivery of anti-tumour drugs. The network is focusing on one of the most promising classes of nanocomposite carriers, inorganic nanoparticles (iNPs) associated to nanoscaled metal organic frameworks (nanoMOFs).


The successful development of this project, involving seven academic, three industrial partners, six partner organisations (5 universities and 1 company), will contribute to the improvement of the highly societal relevant cancer therapy..


Partners: Fundación IMDEA Energía (Coordinator), Universidad de Santiago de Compostela; Centre National de la Recherche Scientifique; Universiteit Antwerpen; Immaterial Labs Ltd; Institut National des Sciences Appliquees de Toulouse; Universitaet Hamburg; Fondazione Istituto Italiano di Tecnologia.; Nanoscale Biomagnetics SL; Isern Patentes Y Marcas M SL.


- Partner Organisations: Universidad Rey Juan Carlos; Universidad de Zaragoza, University of Cambridge; Universite de Nantes; Universita Degli Studi di Genova; Pharmidex.


Funding Institution/Program: This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement Nº 860942.


Call: H2020-MSCA-ITN-2019 (ETN)


https://www.energy.imdea.org/research/projects/heatnmof

February 18, 2025
We’re thrilled to offer Haematology Services to advance drug development and research. Our lab features, the Siemens analyser, delivering precise results across key biological parameters. 🔬 Services Include: Full Blood Count (FBC) Reticulocytes Differential Analysis 🐾 Supporting human and animal models 💡 Applications: Diagnose blood disorders (anaemia, leukaemia and others). Evaluate treatment efficacy in preclinical models. Translate findings from animals to humans. 📦 Sample Details: Minimum 200 µL of EDTA whole blood. Reach out today to learn how we can support your research!
February 13, 2025
We had great fun networking, supporting wellbeing, nurturing our community and raising money for Stevenage based STEMPOINT , the educational charity dedicated to widening access into science, engineering, maths and technology subjects across EastAnglia. Over 30 players took part in the cross-campus sports event, we welcomed teams from GSK, ImmuONE, Tessellate BIO, Neobe Therapeutics, Stevenage Bioscience Catalyst, Pharmidex , MFX, Antikor Biopharma Ltd – and of course STEMPOINT - who came to join us. Congratulations goes to Ash Alavijeh from Pharmidex who won best player of the rally! See you all again in the next badminton tournament in the Spring!
OBN Science Social
February 12, 2025
Pharmidex at OBN Science Social
More Posts
Share by: